Get the Stockscreener App
7.72
2.39%
0.18
After Hours:
7.72
Adverum Biotechnologies Inc stock is traded at $7.72, with a volume of 102.14K.
It is up +2.39% in the last 24 hours and up +2.52% over the past month.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
See More
Previous Close:
$7.54
Open:
$7.53
24h Volume:
102.14K
Relative Volume:
0.55
Market Cap:
$160.58M
Revenue:
-
Net Income/Loss:
$-117.17M
P/E Ratio:
-5.8045
EPS:
-1.33
Net Cash Flow:
$-91.71M
1W Performance:
-0.52%
1M Performance:
+2.52%
6M Performance:
-25.98%
1Y Performance:
-17.10%
1-Day Range:
$7.26
$7.7672
1-Week Range:
$7.17
$8.07
52-Week Range:
$6.38
$29.70
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
Name
Adverum Biotechnologies Inc
Sector
Industry
Phone
(650) 649-1004
Address
100 CARDINAL WAY, REDWOOD CITY, CA
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-22 | Upgrade | Truist | Hold → Buy |
| Jul-23-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-03-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-29-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Apr-29-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Apr-29-21 | Downgrade | Truist | Buy → Hold |
| Dec-16-20 | Initiated | UBS | Neutral |
| Nov-12-20 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jun-26-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| May-05-20 | Upgrade | SunTrust | Hold → Buy |
| Apr-28-20 | Initiated | Goldman | Buy |
| Mar-16-20 | Initiated | SVB Leerink | Outperform |
| Feb-10-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-10-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Oct-15-19 | Reiterated | Chardan Capital Markets | Neutral |
| Sep-13-19 | Reiterated | Chardan Capital Markets | Neutral |
| Jun-14-19 | Resumed | Raymond James | Mkt Perform |
| Nov-02-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-02-18 | Downgrade | SunTrust | Buy → Hold |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-30-18 | Initiated | SunTrust | Buy |
| Feb-15-18 | Resumed | Piper Jaffray | Overweight |
| Oct-12-17 | Initiated | Raymond James | Outperform |
View All
Adverum Biotechnologies Inc Stock (ADVM) Latest News
Adverum Biotechnologies (NASDAQ:ADVM) Price Target Cut to $10.00 by Analysts at Royal Bank of Canada - MarketBeat
Adverum Biotechnologies Advances in Gene Therapy Development - TipRanks
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Adverum Biotechnologies: Q3 Earnings Snapshot - San Antonio Express-News
Adverum Biotechnologies Reports Third Quarter 2024 - GlobeNewswire
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate - The Bakersfield Californian
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones - StockTitan
Assenagon Asset Management S.A. Has $164,000 Stock Holdings in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - MarketBeat
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Short Interest Update - MarketBeat
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Adverum Biotechnologies names new chief commercial officer - Investing.com
Adverum Biotechnologies Appoints Jason L. Mitchell as Chief - GlobeNewswire
Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program - StockTitan
Dimensional Fund Advisors LP Buys 196,884 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - MarketBeat
Adverum Biotechnologies (ADVM) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Squarepoint Ops LLC Raises Holdings in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - MarketBeat
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Shares Purchased by Marshall Wace LLP - MarketBeat
ADVM Stock Sees Surge of Approximately 3.49% in Last Five Days - Knox Daily
Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic - Yahoo Finance
Bet on 5 Top-Ranked Stocks With Rising P/E - Yahoo Finance
Logos Global Management LP Sells 1,083,333 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - MarketBeat
Wall Street SWOT: Adverum Biotechnologies stock faces pivotal year amid trials - Investing.com
Mizuho Initiates Coverage of Adverum Biotechnologies (ADVM) with Buy Recommendation - MSN
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives $28.17 Average Target Price from Analysts - MarketBeat
(ADVM) Trading Advice - Stock Traders Daily
Logos Global Management LP Cuts Stake in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - Defense World
Adverum Biotechnologies (NASDAQ:ADVM) & CRISPR Therapeutics (NASDAQ:CRSP) Head to Head Comparison - Defense World
Adverum Biotechnologies (NASDAQ:ADVM) Share Price Passes Below Two Hundred Day Moving Average of $9.52 - MarketBeat
(ADVM) Investment Analysis - Stock Traders Daily
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences - ForexTV.com
Wall Street Analysts See a 332.28% Upside in Adverum Biotechnologies (ADVM): Can the Stock Really Move This High? - Yahoo Finance
Adverum Biotechnologies Inc (ADVM) rating initates by Oppenheimer - Knox Daily
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Sees Significant Increase in Short Interest - Defense World
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Sees Significant Growth in Short Interest - MarketBeat
Adverum Biotechnologies (NASDAQ:ADVM) Share Price Crosses Above Fifty Day Moving Average of $7.31 - Defense World
Adverum Biotechnologies (NASDAQ:ADVM) Shares Pass Above 50-Day Moving Average of $7.31 - MarketBeat
Adverum Biotechnologies, Inc. Appoints Eric G. Carter to its Board of Directors - Marketscreener.com
The Potential Rise in the Price of Adverum Biotechnologies Inc (ADVM) following insiders activity - Knox Daily
Assenagon Asset Management S.A. Boosts Stock Position in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - MarketBeat
Mizuho cuts Adverum Biotechnologies target to $20 from $22 By Investing.com - Investing.com Canada
(ADVM) Long Term Investment Analysis - Stock Traders Daily
FY2024 EPS Estimates for Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Boosted by Chardan Capital - Defense World
Adverum Biotechnologies, Inc. Forecasted to Earn FY2024 Earnings of ($4.07) Per Share (NASDAQ:ADVM) - MarketBeat
Brokers Offer Predictions for Adverum Biotechnologies, Inc.’s Q3 2024 Earnings (NASDAQ:ADVM) - Defense World
Brokers Issue Forecasts for Adverum Biotechnologies, Inc.'s FY2025 Earnings (NASDAQ:ADVM) - MarketBeat
Adverum Biotechnologies, Inc. to Post FY2025 Earnings of ($4.31) Per Share, Chardan Capital Forecasts (NASDAQ:ADVM) - Defense World
Adverum Biotechnologies (NASDAQ:ADVM) Price Target Cut to $40.00 by Analysts at Truist Financial - Defense World
Adverum Biotechnologies (NASDAQ:ADVM) Upgraded to “Hold” at StockNews.com - Defense World
Adverum Biotechnologies Inc Stock (ADVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adverum Biotechnologies Inc Stock (ADVM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Leonard Braden Michael | 10% Owner |
Jul 17 '24 |
Buy |
7.75 |
135,546 |
1,049,926 |
2,101,546 |
| Leonard Braden Michael | 10% Owner |
Jul 18 '24 |
Buy |
9.11 |
80,718 |
735,736 |
2,182,264 |
| Scopa James Paul | Director |
Feb 07 '24 |
Buy |
1.35 |
100,000 |
135,000 |
100,000 |
| Lupher, Jr. Mark L. | Director |
Feb 07 '24 |
Buy |
1.35 |
130,000 |
175,500 |
130,000 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):